Bioinformatics Institute of IndiaBioinformatics Institute of IndiaBlog of BII Institute.Blog fucus is on Bioinformatics, Biotechnology, Pharma 
Articles
BII Clinical Trial Weekend Program - Join Now
2008-06-06 14:02:00 | View | Upload your ownFor career enhancement programs in emerging life science, pharma and chemical science areas visit www.bii.in/biodlp More About: Join , Weekend , Trial , Program
Regulatory Affairs Professional: In a New Era
2008-06-06 06:55:00 So, what has changed? In short, business. Historically, most regulatory professionals started their professional lives in the R&D laboratories, until beginning their 'retirement' in Regulatory . These days, there are many more healthcare professionals in Regulatory who have intentionally chosen the field as a career, and frequently switch between industry and the regulatory authorities. The best advice companies can obtain is from a combination of ex-regulators combined with that of industry development experts with a business focus. The attitude now is not "We can't do that," but rather "How can we get it done? Within given time and money constraints, how do we get the product onto the market? What is the best route? Which market or markets first?" The best regulatory people work hand-in-hand with marketing and R&D to develop innovative, risk-taking development plans that take advantage of new technological and regulatory developments to accelerate time to market. With ne... More About: Affairs , Professional
Regulatory Professionals: The Hub Of The Wheel
2008-06-05 07:27:00 Pharmaceutical companies' regulatory affairs units are more vital than ever, but, traditionally, they have not been known for their flexibility. Peter Lassoff explains why this image is outdated, and how working more co-operatively with your regulatory department will help to maximize your success in the market place. Experienced regulatory professionals are a very valuable resource for development in a variety of ways. Recently we have seen some dramatic failures to obtain regulatory approval in large blue-chip companies; the quest to find the new aspirin or warfarin is as difficult as ever, and even the largest companies are now reconsidering regulatory strategy as a result.Back in those prehistoric times, Regulatory (or 'Registration', as it was then) was more or less a 'post office,' and the work essentially involved compiling reports written by the experts in R&D and mailing them to the various regulatory authorities.The modern view of regulatory affairs is as a dynami... More About: Wheel , Professionals
The State of Affairs: An Overview of the Regulatory Affairs Profession
2008-06-05 06:43:00 Source:http://sciencecareers.sciencemag.o rg/Regulatory affairs (RA) within the biomedical/health products sector is a relatively young, multidimensional profession that is international in scope. At its core, the RA profession facilitates the collection, analysis, and communication about the risks and benefits of health products to regulatory agencies, medical care systems, and the public. Operationally, RA is responsible for assuring that government obligations, market-driven demands, and evolving scientific conventions are understood and addressed by various stakeholders of the medical and health care system.RA professionals come from a variety of disciplines such as law, academic and industrial research, and medicine. RA is a promising field for scientists searching for alternative careers because it offers a multitude of starting jobs and opportunities for advancement.Regulatory affairs professionals are employed in industry, government, and in academic research and clinical ins... More About: Profession , State , Affairs , The State
Job Openings
2008-06-04 12:48:00 Source: Times Ascent June 04, 2008For career enhancement programs in emerging life science, pharma and chemical science areas visit www.bii.in/biodlp
International Seminar on "Global Clinical Trial Management & Logistics"
2008-06-02 14:25:00 16th International Seminar on "Global Clinical Trial Management & Logistics" is about to held on 6th June 2008.Venue: Renaissance Hotel, MumbaiTopics to be covered:Ethics & GCP: Clinical ResearchPartnerships with CRO'sClinical Trial Trends in IndiaClod Chain ManagementThe Patent Regime & the Present status of R&D in IndiaInvestigtaor Challenges & site Monitoring TechniquesClinical Trials in Emerging MarketsChanges in IATA RegulationsCTM Storage & Distribution in Emerging countiesBioequivalence Studies - Outsourcing ModelsFor further information contact:World Courier India Pvt.Ltd3rd Floor, Freight Wings HouseMakwana Road, MarolAndheri EastMumbai 400059IndiaPhone: 022 - 67102861Email: mumbaiseminar@worldcourier.co.inWeb: www.worldcourier.com/seminar For career enhancement programs in emerging life science, pharma and chemical science areas visit www.bii.in/biodlp
Advantage Ranbaxy in Lipitor case
2008-05-29 06:51:00 In a partial victory for Ranbaxy Laboratories in its patent litigation against Pfizer ,an Australian court has ruled in the Indian company's favour in a case relating to cholesterol lowering drug atorvastatin(Lipitor ).The court at the same also ruled that a proposed Ranbaxy generic product under a different patent infringed Pfizer's basic Lipitor patent (number 601981)Ranbaxy's senior vice president (global intellectual property) Jay Deshmukh said "We are pleased with this decision as it advances the entry of ranbaxy's generic atorvastatin in Australia to May 18,2012"For career enhancement programs in emerging life science, pharma and chemical science areas visit www.bii.in/biodlp More About: Case
BIOTECH INDUSTRIAL TRAINING PROGRAMME(BITP) 2008-09
2008-05-28 07:07:00 For career enhancement programs in emerging life science, pharma and chemical science areas visit www.bii.in/biodlp More About: Training , Industrial , Programme , 2008
New RAPS White Paper Details Career Development Of Regulatory Affairs profe
2008-05-27 07:44:00 SOURCE: Regulatory Affairs Professional Society RAPS has released a new white paper, Regulatory Affairs Professional Development Framework: An Overview, which describes the knowledge, skills and abilities of regulatory professionals. This is the first report of its kind to be published. Download the white paper: http://www.raps.org/pdFramework/White Pape rRegulatory affairs is a dynamic and challenging profession that is vital to making safe and effective healthcare products available worldwide. Regulatory Affairs encompasses a variety of disciplines and job responsibilities, which may begin during the product development and continue into when a product is widely available for use.Individuals who ensure regulatory compliance and prepare submissions as well as those whose main job function is clinical affairs or quality assurance are all considered Regulatory Affairs professionals.Regulatory Affairs professionals are employed in industry, government and academia and are involved with ... More About: Career , Paper , Career Development
Careers In Regulatory Affairs: From Practitioner To Professional
2008-05-22 08:13:00 Larry E. GundersenSource: CenterWatchAvoiding the pitfalls of the regulatory affairs practitioner will distinguish you in this growing field. Findings from a recent survey on employment trends in the clinical trials industry from CenterWatch show that the position in highest demand and with the fastest growth rate is that of regulatory affairs professional. The reasons cited most, in order of popularity: lack of candidates, increased business, and turnover1. Realizing this, those interested in entering or advancing in the field should seek out the proper training2 in order to capitalize on the demand for qualified regulatory affairs professionals.There are two major groups of individuals in regulatory affairs: simple practitioners and truly professional individuals. This article discusses some of the types of regulatory affairs practitioners I have observed in my career, and provides some suggestions about how a regulatory affairs practitioner can become a regulatory affairs profess... More About: Careers , Affairs , Professional , Regulatory
Changing Face Of Drug Regulation
2008-05-21 11:23:00 S LakshmananSource : Pharmabiz.comThe face of Indian regulatory affairs is changing. The government of India is taking enormous steps to showcase India as the destination for multinational companies to conduct their global clinical trials in India. Pharma companies and CROs are keen looking on India since the development cost of a new drug is comparatively one -fifth of other developed countries.The vibrant nature of Indian regulatory affairs is gaining rapidly the attention of world countries since India is turning to be the credible destination. As Indian regulatory affairs increase in complexity and scope, and globalization occurs within the field, there will be constant watch from the developed countries For career enhancement programs in emerging life science, pharma and chemical science areas visit www.bii.in/biodlp More About: Regulation , Changing , Face , Drug
Careers in Regulatory Affairs: A Sure Bet!
2008-05-20 08:19:00 Regulatory affairs is one of the hottest and fasting growing career tracks in the pharmaceutical, biotechnology and medical devices industries. Not surprisingly, due to expansive growth of the biotech and medical devices industries, there are ongoing shortages of regulatory affairs professionals, most notably in the area of regulatory writingFor those of you graduate students and post-doctoral fellows who enjoy writing, are not bored by clinical research and like to work on computers most of the day, a career in regulatory affairs may be right for you! For career enhancement programs in emerging life science, pharma and chemical science areas visit www.bii.in/biodlp More About: Careers , Affairs , Regulatory
Clinical Research Data
2008-05-20 07:34:00 For career enhancement programs in emerging life science, pharma and chemical science areas visit www.bii.in/biodlp More About: Research , Data
MSD PHARMACEUTICALS LAUNCHES NEW ANTI DIABETES DRUG
2008-05-16 11:40:00 On 26 April,MSD Pharmaceuticals ,the Indian arm of Merck&Co., the world's #5 drug maker launched its patented anti-diabetes (type 2) drug,Januvia,in India.Already a best-seller in the US ,the drug uses a new class of molecules that enhances the body's own ability to lower blood sugar when it is elevated.Naveen A . Rao ,the MD of MSD , said that the next on his radar are drugs for other major ailments in the country like dylipidemia( high cholesterol) and cervical cancer ,which is more prevalent than breast cancer among Indian womensource:-Business Today,May 18, 2008For career enhancement programs in emerging life science, pharma and chemical science areas visit www.bii.in/biodlp More About: Diabetes , Drug , Anti
Facts of Indian Biopharma Market
2008-05-16 08:45:00 For career enhancement programs in emerging life science, pharma and chemical science areas visit www.bii.in/biodlp More About: Facts , Market , Indian
Facts of Indian Biopharma Market
2008-05-16 08:44:00 For career enhancement programs in emerging life science, pharma and chemical science areas visit www.bii.in/biodlp More About: Facts , Market , Indian
India's Drug Regulator Can't Be In Isolation
2008-05-16 07:55:00 INDIA'S drug regulatory landscape has changed a lot in the last four-five years,thanks to a clutch of legislative changes and new rules and regulations - new good manufacturing practices through amendments to the Schedule M of Drug s & Cosmetics Act, registration norms for imported drugs, amendments to the ScheduleY that lays down the protocols of regulatory assessments and approvals for manufacturing/import of 'new drugs' and clinical trials, and new norms for medical devices,to name a few.But the regulatory machinery and systems have yet to be in sync with these new laws for their meticulous enforcement and effective delivery of regulatory services.For career enhancement programs in emerging life science, pharma and chemical science areas visit www.bii.in/biodlp More About: Isolation
CLINICAL RESEARCH
2008-05-15 12:13:00 Source: EhealthThe clinical research industry continues to expand, creating new and lucrative vistas of employment. The Average nominal salary growth across all the positions is 4% as against less than 1% for other segments. India?s pharmaceutical market, the second largest in Asia, is growing by over 9% per annum. McKinsey estimates that the outsourced pharmaceutical clinical trial industry will touch INR 5,000 by 2010, requiring 50,000 professionals. As the amount of clinical research expands, a large numbers of researchers, trainers and business development management will be required. Industry analysts expect total clinical research spending in India to increase by more than 30% annually through 2010. Over 250,000 positions remain vacant worldwide and salaries start at Rs. 2.4 lacs p.a. and go to over Rs. 15 lacs p.a. for professional with less than 5 years experience.For career enhancement programs in emerging life science, pharma and chemical science areas visit www.bii.in/bi... More About: Research
RANBAXY INKS DRUG DEALS WITH MERCK
2008-05-15 12:12:00 Source: Times of India: 13th May; 2008(Tuesday) New Delhi: Ranbaxy has signed a collaboration agreement with US-based Merck for drug discovery and clinical development in anti-infective drugs.Ranbaxy and Merck will work together to develop clinically validated anti-bacterial and anti-fungal drug candidates , Ranbaxy will carry out drug discovery and clinical development through Phase IIa clinical trials, with Merck conducting development and commercialization of drug candidates after that.Ranbaxy CEO and MD, Malvinder M Singh told TOI: The agreement has already been signed and returns will start flowing to the company from this (second) quarter it-self?. He, however, didn?t provide details of revenues expected from the deal this year.Ranbaxy will be paid an undisclosed sum, with potential to receive payments over $100 million (per drug) associated with achievement of various R& D regulatory approval for each target included in the collaboration. Ranbaxy will also receive signifi... More About: Drug
PHARMA GAINS FROM DIABETES
2008-05-15 12:11:00 Source: Times of India 6th May?08, (Tuesday)Mumbai: Diabetes , Cardiac and gastrointestinal hold sway in India, where chronic therapies comprise more than 40% of the entire market. Like developed markets, India is gradually shifting to lifestyle disorders. And drug companies are profiting form diabetes and cardiovascular cases.The over searching trend of lifestyle diseases is dictating the fortunes of various therapeutic categories. Prescriptions for diabetes have grown over 15% compounded since 2000 in urban India. With India poised to have the largest number diabetics in future, the antidiabetic therapeutic area has had the highest growth rate of 26.1%, followed by cardiology at 21.3% and gynaecology at 18.3%, according to ORG-IMS data. The antidiabetic segment has grown from 19.5 %( MAT December 2006) to 26.1%(MAT December 2007). The gynaecology segment too recorded growth from 15.9% to 18.3% m during the same period.Not only are drug majors benefiting from the growing cases of di... More About: Pharma
PHARMA GAINS FROM DIABETES
2008-05-15 12:10:00 Source: Times of India 6th May?08, (Tuesday)Mumbai: Diabetes , Cardiac and gastrointestinal hold sway in India, where chronic therapies comprise more than 40% of the entire market. Like developed markets, India is gradually shifting to lifestyle disorders. And drug companies are profiting form diabetes and cardiovascular cases.The over searching trend of lifestyle diseases is dictating the fortunes of various therapeutic categories. Prescriptions for diabetes have grown over 15% compounded since 2000 in urban India. With India poised to have the largest number diabetics in future, the antidiabetic therapeutic area has had the highest growth rate of 26.1%, followed by cardiology at 21.3% and gynaecology at 18.3%, according to ORG-IMS data. The antidiabetic segment has grown from 19.5 %( MAT December 2006) to 26.1%(MAT December 2007). The gynaecology segment too recorded growth from 15.9% to 18.3% m during the same period.Not only are drug majors benefiting from the growing cases of di... More About: Pharma
Ranbaxy gets patent boost in Lipitor battle(T.O.I.,29-4-08)
2008-05-10 06:20:00 India's Ranbaxy Laboratories has received a boost in its patent litigation with Pfizer over cholesterol lowering drug Lipitor , with the US Patent and Trademarks Office rejecting the world's biggest pharma firm's request for reissue of patent. Lipitor is the world's largest selling drug and the two comp[anies are engaged in patent infringement battles in various geographies, including U.K. and other countries in Europe.Originally the Lipitor patent is scheduled to expire in June 2011For career enhancement programs in emerging life science, pharma and chemical science areas visit www.bii.in/biodlp More About: Battle , Boost
US puts India on watch list for IPR violations(T.O.I,30-4-08)
2008-05-10 06:18:00 The US govt. has put India on its 'Priority Watch List ',along with nine other countries ,saying that the country's failure to protect Intellectual Property Rights is putting health, safety and jobs of its citizens at risk.According to US trade representative Susan Schawb "Pirates not only steal ideas they steal jobs and too often they threaten our health and safety"For career enhancement programs in emerging life science, pharma and chemical science areas visit www.bii.in/biodlp
Bioinformatics Institute of India participated in Bangalore Bio 2008
2008-05-09 09:50:00 Bangalore Bio is the flagship event on Biotechnology held annually in Bangalore, India . Over the past 4 years, it has emerged as the India's Biggest Biotech Show. Dr. Kumud Sarin, Program Director of Bioinformatics Institute of India had participated in this huge event held at Bangalore International Exhibition Centre, Bangalore from 24-26th April, 2008 .Objectives of ParticipationCreating awareness about potential of Bioinformatics among students and professionalsCreating awareness about BII courses to visitors, Institutional visitors from India and overseasInteraction with existing BII Correspondence program students.To discuss the business opportunities and tie-ups with Corporates.The event comprises of International Conference, Trade Show (Biotech Expo), RICH (Research Industry Collaboration Hub) to bridge the innovations to investors, Networking Dinners & B2B Forum to facilitate business meetings and many other avenues for forging alliances and form collaborations for the s... More About: Bangalore
GENE THERAPY RESTORES VISION
2008-05-07 11:50:00 Source: Hindustan times 29th April, 2008Persons with congenital retinal disease get partial sight with experimental method in the USAn experimental gene therapy has helped restore partial vision to persons with congenial retinal disease, according to studies published Sunday in a breakthrough which provides hope for treating various eye illnesses.In one study, clinical trials showed success on 3 young adults at children?s hospital of the Philadelphia who suffered from a rare and as yet incurable form of congenital blindness.The retinal degenerations include leber congenital amaurosis, or LCA, a group of diseases that affect light receptors in the retina beginning in early childhood and often causing total blindness in patients in their twenties or thirties.?This result is important for the enter field of gene therapy?. study leader Katherine High was quoted as saying in a new England Journal of Medicine whose website reported the findings by a collection of internati... More About: Therapy , Gene , Vision , Gene Therapy
BII successfully conducted exams all over India
2008-05-02 09:29:00 Bioinformatics Institute of India (BII) successfully conducted exams for the various programs offered by the institution on 26th & 27th April, 2008 all over the India.The examination was conducted on 15 centers across the India for the various industry programs offered by the institute. Thousands of students across the India appeared in the examination on 26th & 27th April 2008 at the following centers all over the India:Noida, Pune, Bangalore, Hyderabad, Chennai, Calcutta, Ahmedabad, Mumbai, Chandigarh, Kottayam, Patna, Lucknow etc.Bioinformatics Institute of India is a premier and reputed Bioinformatics institution for the promotion, growth and prosperity of bioinformatics, Biotechnology, Pharma, Clinical Trial & allied sciences. The aim and vision of the institute is to provide a platform for individuals, professionals, R&D Organizations, Pharmaceutical & Software companies to utilize and harness the Indian bioinformatics potential.The institute aims not only ... More About: Exams
Jubilant Organosys Acquires Clinical Research Organization (CRO) in USA
2008-05-01 08:40:00 Jubilant Organosys Ltd. (Jubilant),an integrated pharmaceuticals company, has acquired Target Research Associates, Inc. (Target), a US-based, full service Clinical ResearchOrganization (CRO). This is the first ever acquisition of a U.S. CRO by anIndian company, and it represents a major initiative supporting Jubilant'splan to expand its CRO services globally. This acquisition makes Jubilant thelargest Indian CRO having operations in India and USA. Jubilant providesproducts and services to the global life sciences industry and has reportedrevenues of US$ 270 million in its fiscal year ended 31st March 2005. Jubilant has acquired a 100% equity stake in Target for a payment of US$33.5 million in cash. The purchase price assumes zero closing working capitalon the date of acquisition and is subject to adjustment in case of any changein working capital. Target is a debt free company with a healthy EBITDAmargin, and it has been consistently profitable with a solid operating base inthe CRO ...
S KOREA AHEAD CHINA CATCHING UP WITH INDIA
2008-04-25 09:35:00 THE ECONOMIC TIMES NEW DELHI FRIDAY 25 APRIL 2008The fast growing clinical trials industry in the country is facing stiff competition from Asian countries like china and South Korea . While South Korea has already surged ahead of India , china is also fast catching up.According to the USFDA registry of ‘industry - sponsored active clinical trials.’ South Korea is conducting 282 trials and the number is growing almost 80%. Compared to this Indian companies is carrying out 236 studies and growing at 61%.China is not far behind with 150 studies and growing at 64%,says Pfizer director (medical & regulatory affairs) Dr Chandrasekhar Potkar.Currently‘s India’s clinical trials industry is estimated to be around $300 million and projected to touch $2billion by 2010.However.this still a small pie of the global outsourcing market estimated to be around $30 billion.’ Amongst Asian countries, India had a headstart having initiated global clinical research more than a decade ago. Cou... More About: Ahead , S Korea
BII Noida introduces Advance Program in Clinical Trials
2008-04-18 11:54:00 Bioinformatics Institute of India is happy to introduce 9 months weekend Advance Program in Clinical Trials . The main objective of the course is to provide students with a theoretical and practical understanding of the issues involved in the design, conduct, analysis and interpretation of clinical trials.Program MethodologyProspective participants may join the program by submitting the application form along with the necessary Fees and attachments.Lecture classes for the program would be taken by expertise facultyGuest faculty from industry and academia would also deliver the lectureStudents would be taken for Clinical site visits to various hospitals etc.Along with the regular classes students would also be provided with the practical industry oriented knowledge of the subject .e.g. ? Role of Computers in Clinical trial etc.E-learning platform via Moodle would also be provided to students Program DurationThe Program Duration is 9 months. Program EligibilityThe eligibility for the t... More About: Noida
Project Proposals for Bioinformatics Trainee
More articles from this author:2008-04-11 09:52:00 1-2 months Project Project-IWe?ll consider the human genome.Scan the human genome for at least 5 putative genes.Apply different bioinformatics tools.The gene which gives the best or interesting result, select it.Further gene analysis can be carried out using several other tools.Project-II1. The members of a protein family have regions that are shared by many of them and other regions that show high variability.1. Choose a family of proteins.2. Compare several family members (at least 20).3. Give possible explanations for the regions of conservation /variability.6 months ProjectProject I1. Consider any one biochemical pathways present in a wide range of organisms for example -glycolysis (the degradation of glucose into to create energy (ATP)).2. Choose a pathway that is shared by at least 3 different organisms.3. Check which parts of the pathway are shared, and the degree of similarity between the shared components.4. Explain why some parts of the path... More About: Trainee , Bioinformatics 1, 2, 3, 4 |
|
 |
|
 |
